Tag: DPHARMA

Financial News Report DPHARMA: Strong Earnings Beat Expectations on Strategic Efficiencies, Positive Outlook Maintained Investment Bank TA SECURITIES TP (Target Price) RM0.25 (+25.0%) Last Traded RM0.20 Recommendation BUY A leading pharmaceutical company has reported a significant overperformance in its nine-month financial results, with net profit for 9M25 reaching RM68.4 million. This figure comfortably surpassed the…

Pharmaceutical Firm Exceeds Expectations DPHARMA: Pharmaceutical Firm Exceeds Expectations on Robust Sales and Margin Growth Investment Bank TA SECURITIES TP (Target Price) RM0.25 (+25.0%) Last Traded RM0.20 Recommendation BUY A prominent pharmaceutical company reported core earnings for the first nine months of 2025 that were well within market expectations, driven by strong public sector sales…

“`html Investment Report Analysis DPHARMA: Earnings Surpass Expectations Driven by Cost Controls, Positive Outlook Affirmed Investment Bank TA SECURITIES TP (Target Price) RM0.25 (+25.0%) Last Traded RM0.20 Recommendation BUY The company reported a solid financial performance for the nine months ended 9M25, with net profit aligning with both internal and consensus expectations. The robust results…

Duopharma Biotech: Strong Performance and Positive Outlook RHB Small Cap Asean Research 22 August 2025 Duopharma Biotech (DBB MK): Strong Performance and Positive Outlook On a Solid Footing; Maintain BUY Shariah Compliant Malaysia Results Review Consumer Non-cyclical | Pharmaceuticals Keep BUY and DCF-derived MYR1.56 TP, 18% upside and c.2% FY25F yield. Duopharma Biotech booked 2Q25…